Anlon Healthcare IPO Subscription Status Day 3: Subscribed 7.12 Times

Anlon Healthcare Limited's initial public offering (IPO) has demonstrated strong investor interest through its third and final day of subscription, with Anlon Healthcare's stock price set at ₹86-91 per share reflecting positive market reception. The ₹121.03 crore IPO reached 7.12 times by 5:04:36 PM on day three, indicating strong investor interest in this pharmaceutical manufacturing company incorporated in 2013.

Anlon Healthcare IPO retail investors segment leads with exceptional 47.26 times subscription, whilst non-institutional investors demonstrate strong participation at 10.61 times and qualified institutional buyers (ex-anchor) show modest interest at 1.07 times, reflecting positive investor confidence in this company.

Anlon Healthcare IPO subscription reached strong 7.12 times on day three, led by Retail Investors (47.26x), Non-Institutional Investors (10.61x), and Qualified Institutional Buyers Ex-Anchor (1.07x). Total applications reached 3,34,669.

Subscription Status of Anlon Healthcare IPO:

Here are the subscription details for Anlon Healthcare IPO as of Day 3 (August 29, 2025, 5:04:36 PM):

Anlon Healthcare IPO Reservation

Key Highlights - Day 3:

• Overall subscription reached strong 7.12 times, showing substantial improvement from day two's 3.30 times.
• Retail investors category displaying exceptional interest at 47.26 times, building substantially from day two's 22.33 times
• Non-institutional investors displaying strong confidence at 10.61 times, building substantially from day two's 2.09 times
• Qualified institutional buyers (ex-anchor) showing modest growth at 1.07 times, building marginally from day two's 1.01 times
• Total applications reached 3,34,669, indicating strong investor participation for this mainboard IPO
• Cumulative bid amount reached ₹861.85 crores, significantly exceeding the issue size of ₹121.03 crores

Anlon Healthcare IPO - Day 2 Subscription at 3.30 Times

Key Highlights - Day 2:

• Overall subscription reached strong 3.30 times, showing substantial improvement from day one's 1.69 times.
• Retail investors category displaying exceptional interest at 22.33 times, building substantially from day one's 8.99 times
• sNII segment showing strong performance at 3.51 times, building substantially from day one's 1.16 times
• Non-institutional investors displaying moderate growth at 2.09 times, building substantially from day one's 0.71 times
• bNII category demonstrating modest performance at 1.38 times, building substantially from day one's 0.48 times
• Qualified institutional buyers (ex-anchor) showing modest improvement at 1.01 times, building from day one's 0.91 times
• Total applications reached 1,53,410, indicating strong investor participation for this mainboard IPO
• Cumulative bid amount reached ₹399.90 crores, significantly exceeding the issue size of ₹121.03 crores

Anlon Healthcare IPO - Day 1 Subscription at 1.69 Times

Key Highlights - Day 1:

• Overall subscription reached moderate 1.69 times, showing mixed initial investor response.
• Retail investors demonstrating exceptional confidence at 8.99 times, indicating strong retail appetite for pharmaceutical sector opportunity
• Qualified institutional buyers (ex-anchor) showing moderate performance at 0.91 times, indicating cautious institutional assessment on opening day
• Non-institutional investors category displaying limited interest at 0.71 times, with sNII segment performing better at 1.16 times while bNII showing restrained participation at 0.48 times
• Total applications reached 61,111, indicating reasonable investor participation for this mainboard IPO
• Cumulative bid amount reached ₹204.33 crores, exceeding the issue size of ₹121.03 crores
• Strong retail demand offset by cautious institutional response, creating mixed subscription pattern typical of specialized pharma offerings

About Anlon Healthcare Limited

Incorporated in 2013, Anlon Healthcare Limited is an Indian pharmaceutical manufacturing company engaged in manufacturing pharmaceutical intermediates and active pharmaceutical ingredients (APIs), specializing in high-purity pharmaceutical products for medicines, nutraceuticals, personal care and animal health sectors with Drug Master File approvals from global regulatory authorities including ANVISA, NMPA and PMDA.